Equities Analysts Issue Forecasts for Korro Bio Q1 Earnings

Korro Bio, Inc. (NASDAQ:KRRO) – William Blair issued their Q1 2025 EPS estimates for shares of Korro Bio in a report issued on Tuesday, March 18th. William Blair analyst M. Minter expects that the company will post earnings of ($2.91) per share for the quarter. The consensus estimate for Korro Bio’s current full-year earnings is ($9.52) per share. William Blair also issued estimates for Korro Bio’s Q2 2025 earnings at ($2.98) EPS, Q3 2025 earnings at ($3.02) EPS, Q4 2025 earnings at ($3.05) EPS, FY2025 earnings at ($11.95) EPS, Q1 2026 earnings at ($3.11) EPS, Q2 2026 earnings at ($3.14) EPS, Q3 2026 earnings at ($3.17) EPS, Q4 2026 earnings at ($3.20) EPS and FY2026 earnings at ($12.61) EPS.

Several other equities analysts have also commented on the company. Royal Bank of Canada lowered their price objective on Korro Bio from $105.00 to $95.00 and set an “outperform” rating for the company in a research report on Wednesday. Oppenheimer began coverage on shares of Korro Bio in a research report on Friday, January 10th. They set an “outperform” rating and a $155.00 price target for the company. Finally, HC Wainwright reissued a “buy” rating and set a $115.00 price objective on shares of Korro Bio in a research note on Thursday. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Korro Bio presently has a consensus rating of “Buy” and a consensus price target of $142.57.

Korro Bio Stock Performance

NASDAQ KRRO opened at $23.76 on Friday. The stock’s 50 day moving average is $29.88 and its 200 day moving average is $41.37. Korro Bio has a twelve month low of $18.50 and a twelve month high of $98.00.

Korro Bio (NASDAQ:KRRO) last posted its earnings results on Tuesday, March 18th. The company reported ($2.26) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.33) by $0.07. The firm had revenue of $2.27 million for the quarter.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Quest Partners LLC raised its holdings in Korro Bio by 172.1% in the 3rd quarter. Quest Partners LLC now owns 1,777 shares of the company’s stock worth $59,000 after acquiring an additional 1,124 shares during the last quarter. Brown Brothers Harriman & Co. increased its holdings in shares of Korro Bio by 251.0% in the 3rd quarter. Brown Brothers Harriman & Co. now owns 2,854 shares of the company’s stock worth $95,000 after purchasing an additional 2,041 shares in the last quarter. BNP Paribas Financial Markets increased its holdings in shares of Korro Bio by 1,018.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 4,909 shares of the company’s stock worth $164,000 after purchasing an additional 4,470 shares in the last quarter. MetLife Investment Management LLC raised its stake in shares of Korro Bio by 129.0% in the third quarter. MetLife Investment Management LLC now owns 3,639 shares of the company’s stock worth $122,000 after purchasing an additional 2,050 shares during the last quarter. Finally, State Street Corp lifted its holdings in shares of Korro Bio by 18.9% during the third quarter. State Street Corp now owns 118,765 shares of the company’s stock valued at $3,969,000 after purchasing an additional 18,877 shares in the last quarter. Institutional investors own 13.18% of the company’s stock.

About Korro Bio

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).